How many drugs treat Rheumatoid Arthritis?

Drug Landscape tracks 10 marketed treatments for Rheumatoid Arthritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/rheumatoid-arthritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Rheumatoid Arthritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Rheumatoid Arthritis (Immunology & Inflammation) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

Immunology & Inflammation 10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Rheumatoid Arthritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Jyseleca	FILGOTINIB	Gilead Sciences Ireland UC		Tyrosine-protein kinase JAK1	2020-01-01
Olumiant	baricitinib	Eli Lilly	Janus Kinase Inhibitor [EPC]	Tyrosine-protein kinase JAK2	2018-01-01
Xeljanz	Tofacitinib Citrate	Pfizer	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Xeljanz	tofacitinib	Pfizer	JAK inhibitor	Janus kinase (JAK) enzymes	2012-01-01
Roactemra	tocilizumab	Roche	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
Simponi	GOLIMUMAB	Centocor Ortho Biotech Inc	Tumor Necrosis Factor Blocker [EPC]	Tumor necrosis factor	2009-01-01
Cimzia	CERTOLIZUMAB PEGOL	UCB	Tumor Necrosis Factor Blocker [EPC]	TNFα	2008-01-01
Orencia	abatacept	Bristol-Myers Squibb	Selective T cell costimulation modulator	CD80, CD86, CD28	2005-01-01
Humira	ADALIMUMAB	AbbVie	TNF blocker	Tumor Necrosis Factor-alpha (TNF-alpha)	2002-01-01
Abrilada	Adalimumab-Afzb	AbbVie	TNF blocker	Tumor necrosis factor-alpha (TNF-alpha)	2002-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 27 drugs in Rheumatoid Arthritis
Pfizer · 17 drugs in Rheumatoid Arthritis
Roche · 4 drugs in Rheumatoid Arthritis
Sanofi · 3 drugs in Rheumatoid Arthritis
Johnson & Johnson · 3 drugs in Rheumatoid Arthritis
Biovitrum Ab · 2 drugs in Rheumatoid Arthritis
AbbVie · 2 drugs in Rheumatoid Arthritis
Legacy Pharma · 2 drugs in Rheumatoid Arthritis
Bristol-Myers Squibb · 2 drugs in Rheumatoid Arthritis
Generic (originally Schering) · 2 drugs in Rheumatoid Arthritis
Chugai Pharmaceutical · 1 drug in Rheumatoid Arthritis
Biocad · 1 drug in Rheumatoid Arthritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Rheumatoid Arthritis:

Cite this brief

Drug Landscape (2026). Rheumatoid Arthritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/rheumatoid-arthritis. Accessed 2026-06-10.

Rheumatoid Arthritis full disease profile — treatment pathway, diagnostics, guidelines
Immunology & Inflammation area landing
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing